Evidence map›Paper›PMID 40338304›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2025

Measurement of cyclosporin induced changes in P-glycoprotein function at the human blood-brain barrier using [

Pascalle Mossel, Giordana Salvi de Souza, Antoon T M Willemsen, Gilles N Stormezand, Nicola A Colabufo, Jun Toyohara, Hendrikus H Boersma, Rudi A J O Dierckx, Adriaan A Lammertsma, Anna L Bartels and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. FromACS omega · 2026
    Article
  2. Review
  3. Article
  4. Evaluating image-derived input functions for cerebral [Frontiers in nuclear medicine · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Pascalle MosselDepartment of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Giordana Salvi de SouzaDepartment of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Antoon T M WillemsenDepartment of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Gilles N StormezandDepartment of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Nicola A ColabufoDipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari "A. Moro", via Orabona, 4, 70125, Bari, Italy.
Jun ToyoharaResearch Team for Neuroimaging, Tokyo Metropolitan Institute of Gerontology, 35-2 Sakae-cho, Itabashi-ku, Tokyo, 1730015, Japan.
Hendrikus H BoersmaDepartment of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Rudi A J O DierckxDepartment of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Adriaan A LammertsmaDepartment of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Anna L BartelsDepartment of Neurology, Ommelander Ziekenhuis Groep, Scheemda, The Netherlands.
Gert LuurtsemaDepartment of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. g.luurtsema@umcg.nl.

Funding

Siemens Healthineers C0022757517
6 · The paper itself

Abstract

introductionP-glycoprotein (P-gp) or multidrug-resistance protein is one of the most extensively studied efflux transporters at the blood-brain barrier (BBB). Changes in P-gp function are associated with several neurodegenerative and psychiatric diseases, including Alzheimer's disease, Parkinson's disease and schizophrenia and with the bioavailability of several pharmaceuticals in the brain, causing multi-drug resistance or side effects. PET imaging can be used to measure the P-gp function in vivo. This study aims to validate [

methodsFourteen healthy volunteers (age 67 ± 5y) were included. Subjects underwent twice a 60 min dynamic [

resultsNo significant difference was found in plasma kinetics, plasma curves, plasma-to-whole blood ratio, and the parent fraction of the baseline scans and scans after administration of cyclosporin. Volume of distribution values in whole brain grey matter showed a significant increase (6.18 ± 1.29 to 9.00 ± 1.29 mL·cm

conclusionThe outcomes of the current study reflect the potential ability of [

trial registrationEudraCT 2020-001564-28.

Indexed as

ATP Binding Cassette Transporter, Subfamily B, Member 1Blood-Brain BarrierCyclosporinePositron-Emission TomographyAgedFemaleFluorine RadioisotopesHumansMaleMiddle AgedRadiopharmaceuticalsATP Binding Cassette Transporter, Subfamily B, Member 1CyclosporineFluorine RadioisotopesRadiopharmaceuticalsBBBCsAP-gpPharmacologyPositron emission tomography

Identifiers

PMID40338304
PMCPMC12491356

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.